Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SNSE

Sensei Biotherapeutics Inc

Dec 11 • 04:00PM ET

0.4350

Dollar change -0.0350
Percentage change -7.45	%

Healthcare • Biotechnology • USA • NASD

Peers: XNCR ADAP CLLS FATE CRSP ONVO ACHL BNTX BLUE

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.19	Insider Own	34.24%	Shs Outstand	25.15M	Perf Week	-13.00%
Market Cap	10.94M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	0.00%	Shs Float	16.54M	Perf Month	-19.44%
Income	-29.80M	PEG	-	EPS next Q	-0.28	Inst Own	8.84%	Short Float	1.37%	Perf Quarter	-13.00%
Sales	0.00M	P/S	-	EPS this Y	4.10%	Inst Trans	4.63%	Short Ratio	0.51	Perf Half Y	-35.56%
Book/sh	1.82	P/B	0.24	EPS next Y	25.36%	ROA	-44.18%	Short Interest	0.23M	Perf Year	-34.75%
Cash/sh	1.87	P/C	0.23	EPS next 5Y	-	ROE	-51.04%	52W Range	0.38 - 1.94	Perf YTD	-37.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.26%	ROI	-62.33%	52W High	-77.58%	Beta	0.16
Dividend TTM	-	Quick Ratio	8.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.28%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	8.84	EPS Y/Y TTM	9.61%	Oper. Margin	-	RSI (14)	40.10	Volatility	9.59% 13.07%
Employees	27	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.17
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	-3.30%	Payout	-	Rel Volume	0.69	Prev Close	0.47
Sales Surprise	-	EPS Surprise	6.99%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	446.68K	Price	0.44
SMA20	-13.24%	SMA50	-15.23%	SMA200	-42.99%	Trades		Volume	307,783	Change	-7.45%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Initiated	Stephens	Overweight	$5
Jul-01-21	Downgrade	Berenberg	Buy → Hold	$12
Jun-29-21	Downgrade	Oppenheimer	Outperform → Perform	$30 → $14
Mar-01-21	Initiated	Piper Sandler	Overweight	$25
Mar-01-21	Initiated	Oppenheimer	Outperform	$36
Mar-01-21	Initiated	Citigroup	Buy	$30
Mar-01-21	Initiated	Berenberg	Buy	$27

Nov-27-24 04:05PM	Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -13.06%
Oct-29-24 07:30AM	Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences (GlobeNewswire)
Sep-04-24 04:05PM	Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference (GlobeNewswire)
07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
01:53PM	Loading…
Aug-06-24 01:53PM	SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024 (InvestorPlace) +6.56%
07:30AM	Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-30-24 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -11.07%
May-24-24 08:27AM	Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? (InvestorPlace) -45.52%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-23-24 05:10PM	Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 (GlobeNewswire) +6.62%
May-09-24 01:54PM	SNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024 (InvestorPlace) -14.67%
07:30AM	Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-24 04:05PM	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-09-24 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference (GlobeNewswire) +6.28%
04:05PM	Loading…
Apr-04-24 04:05PM	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment (GlobeNewswire)
Mar-22-24 07:30AM	Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium (GlobeNewswire) +11.43%
Mar-06-24 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences (GlobeNewswire)
Feb-28-24 07:30AM	Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +9.09%
Feb-07-24 07:30AM	Sensei Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) +6.12%
Jan-04-24 07:30AM	Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Nov-07-23 08:09AM	Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results (GuruFocus.com) -7.15%
07:30AM	Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-23 04:05PM	Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire) -13.75% +9.42%
Nov-01-23 07:30AM	Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer (GlobeNewswire) +15.33%
Oct-25-23 09:05AM	Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting (GlobeNewswire)
Oct-23-23 07:30AM	Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 (GlobeNewswire)
Sep-27-23 07:30AM	Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo (GlobeNewswire) -10.17%
Sep-21-23 07:30AM	Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
Sep-13-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference (GlobeNewswire)
07:30AM	Loading…
Aug-30-23 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-03-23 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors (GlobeNewswire)
Jun-01-23 07:30AM	Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors (GlobeNewswire)
May-31-23 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 07:30AM	Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-20-23 07:30AM	Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Apr-18-23 04:05PM	Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Apr-13-23 07:30AM	Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-30-23 07:30AM	Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium (GlobeNewswire) +6.11%
Mar-28-23 07:30AM	Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-23-23 11:56AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 07:30AM	Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody (GlobeNewswire)
Mar-14-23 04:35PM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) +9.92%
Mar-07-23 05:15PM	Sensei Biotherapeutics Adopts Stockholder Rights Agreement (GlobeNewswire) +6.49%
Mar-06-23 07:30AM	Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 07:30AM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire) -7.14%
Feb-16-23 07:30AM	Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-14-23 07:30AM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics (GlobeNewswire)
Feb-06-23 07:30AM	Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
Jan-05-23 07:30AM	Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors (GlobeNewswire)
Dec-08-22 01:10PM	Immunotherapy startup shutters Boston research site, lays off 17 (American City Business Journals)
10:40AM	Sensei Biotherapeutics Slashes Workforce, Closes R&D Site (Benzinga)
07:30AM	Sensei Biotherapeutics Provides Update on Strategic Priorities (GlobeNewswire)
Nov-22-22 07:30AM	Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-21-22 07:30AM	Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody (GlobeNewswire)
06:00AM	Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate (GlobeNewswire)
Nov-10-22 09:00AM	Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) +9.49%
Nov-08-22 07:30AM	Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-22 07:30AM	Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint (GlobeNewswire)
Nov-02-22 07:30AM	Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference (GlobeNewswire)
Oct-14-22 10:22AM	We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate (Simply Wall St.)
Oct-05-22 08:05AM	Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-30-22 04:05PM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) +7.10%
Sep-21-22 04:05PM	Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival (GlobeNewswire) -5.32%
Aug-31-22 07:30AM	Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody (GlobeNewswire)
Aug-23-22 07:30AM	Sensei Biotherapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 07:02AM	One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year (Simply Wall St.)
Aug-09-22 07:30AM	Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -5.37%
Jun-01-22 07:30AM	Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer (GlobeNewswire)
May-25-22 07:30AM	Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference (GlobeNewswire) -6.32%
May-10-22 07:30AM	Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +9.80%
May-07-22 09:40AM	Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Apr-21-22 09:09AM	9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller (Insider Monkey)
Mar-10-22 07:30AM	Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights (GlobeNewswire) -7.62%
Mar-09-22 04:05PM	Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors (GlobeNewswire) +6.49%
Mar-03-22 07:30AM	Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -5.36%
Feb-11-22 07:30AM	Sensei Biotherapeutics to Participate in Citis 2022 Virtual Immuno-Oncology Summit (GlobeNewswire)
Jan-17-22 11:22AM	Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months (Simply Wall St.)
Jan-06-22 08:00AM	Sensei Biotherapeutics Announces Executive Promotions (GlobeNewswire)
Dec-16-21 09:01AM	Sensei Biotherapeutics Named a Winner of Comparablys Best CEO Award (GlobeNewswire)
Dec-13-21 04:01PM	Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-19-21 04:02PM	Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire) -5.69%
Nov-17-21 10:37AM	What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own? (Simply Wall St.) -5.10%
Nov-12-21 07:02AM	Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire) +11.09%
Nov-09-21 08:54AM	Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights (GlobeNewswire)
Nov-03-21 09:01AM	Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021 (GlobeNewswire)
Oct-01-21 08:05AM	Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Aug-17-21 01:56PM	Here's Why We're Not Too Worried About Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation (Simply Wall St.)
Aug-09-21 12:00PM	Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why (Zacks)
Aug-04-21 07:45AM	Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program (GlobeNewswire)
Aug-02-21 08:01AM	Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors (GlobeNewswire)
Jun-29-21 01:49PM	These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday (Motley Fool) -15.97%
Jun-28-21 04:05PM	Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs (GlobeNewswire)
May-19-21 05:03PM	Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck (GlobeNewswire) +5.42% +30.11%
May-12-21 07:41AM	Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update (GlobeNewswire)
May-05-21 08:05AM	Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board (GlobeNewswire)
May-04-21 07:18AM	What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own? (Simply Wall St.) -8.48%

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNSE

Sensei Biotherapeutics Inc

Upgrade your FINVIZ experience